Table: Santen Pharm -6-MTH group results (IFRS)

SANTEN PHARMACEUTICAL

06/11/2019 06:00

Nov 6 (Reuters)- 
              Santen Pharmaceutical Co Ltd 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   6 months ended      6 months ended       Year to 
                  Sep 30, 2019        Sep 30, 2018     Mar 31, 2020 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales              118.78              114.34           248.00    
                   (+3.9 pct)          (+3.2 pct)       (+6.0 pct)  
  Operating           19.01               20.83            34.50    
                   (-8.7 pct)          (-1.0 pct)       (-23.5 pct) 
  Pretax              18.41               19.79            34.30    
                   (-7.0 pct)          (-4.3 pct)       (-20.4 pct) 
  Net                 13.15               14.38                     
                   (-8.6 pct)          (-5.7 pct)                   
  EPS Basic         32.94 yen           35.34 yen        58.98 yen  
  EPS Diluted       32.85 yen           35.23 yen                   
  Ann Div                               26.00 yen        27.00 yen  
  -Q2 Div           13.00 yen           13.00 yen                   
  -Q4 Div                               13.00 yen        14.00 yen  
 
  NOTE - Santen Pharmaceutical Co Ltd. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T